Bibliography: Schizophrenia: Advances in Understanding and Treatment

Overview

Journal Focus (Am Psychiatr Publ)

Specialty Medical Education

Date 2020 Jan 31

PMID 31997956

Affiliations

Soon will be listed here.

References

Cristobal-Narvaez P, Sheinbaum T, Ballespi S, Mitjavila M, Myin-Germeys I, Kwapil T . Impact of Adverse Childhood Experiences on Psychotic-Like Symptoms and Stress Reactivity in Daily Life in Nonclinical Young Adults. PLoS One. 2016; 11(4):e0153557. PMC: 4833319. DOI: 10.1371/journal.pone.0153557. View

Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R . Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2011; 200(1):22-9. DOI: 10.1192/bjp.bp.109.066357. View

Greenwood T, Swerdlow N, Gur R, Cadenhead K, Calkins M, Dobie D . Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013; 170(5):521-32. PMC: 3878873. DOI: 10.1176/appi.ajp.2012.12020186. View

Keshavan M, Vinogradov S, Rumsey J, Sherrill J, Wagner A . Cognitive training in mental disorders: update and future directions. Am J Psychiatry. 2014; 171(5):510-22. PMC: 4114156. DOI: 10.1176/appi.ajp.2013.13081075. View

Connery H . Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015; 23(2):63-75. DOI: 10.1097/HRP.0000000000000075. View

Tek C, Kucukgoncu S, Guloksuz S, Woods S, Srihari V, Annamalai A . Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2015; 10(3):193-202. PMC: 5589463. DOI: 10.1111/eip.12251. View

Cerimele J, Durango A . Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J Clin Psychiatry. 2012; 73(8):e1039-47. DOI: 10.4088/JCP.11r07410. View

Mueser K, Penn D, Addington J, Brunette M, Gingerich S, Glynn S . The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. Psychiatr Serv. 2015; 66(7):680-90. PMC: 4490051. DOI: 10.1176/appi.ps.201400413. View

Bechtold J, Hipwell A, Lewis D, Loeber R, Pardini D . Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms. Am J Psychiatry. 2016; 173(8):781-9. PMC: 5390686. DOI: 10.1176/appi.ajp.2016.15070878. View

10.

Clemmensen L, Vernal D, Steinhausen H . A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012; 12:150. PMC: 3521197. DOI: 10.1186/1471-244X-12-150. View

11.

Bentall R, De Sousa P, Varese F, Wickham S, Sitko K, Haarmans M . From adversity to psychosis: pathways and mechanisms from specific adversities to specific symptoms. Soc Psychiatry Psychiatr Epidemiol. 2014; 49(7):1011-22. DOI: 10.1007/s00127-014-0914-0. View

12.

Kane J, Robinson D, Schooler N, Mueser K, Penn D, Rosenheck R . Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2015; 173(4):362-72. PMC: 4981493. DOI: 10.1176/appi.ajp.2015.15050632. View

13.

Green M, Horan W, Lee J . Social cognition in schizophrenia. Nat Rev Neurosci. 2015; 16(10):620-31. DOI: 10.1038/nrn4005. View

14.

Kranzler H, Cohen S . Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child Adolesc Psychiatr Clin N Am. 2013; 22(4):727-44. DOI: 10.1016/j.chc.2013.06.002. View

15.

Laurens K, Luo L, Matheson S, Carr V, Raudino A, Harris F . Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry. 2015; 15:205. PMC: 4548447. DOI: 10.1186/s12888-015-0562-2. View

16.

Kane J, Zukin S, Wang Y, Lu K, Ruth A, Nagy K . Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. J Clin Psychopharmacol. 2015; 35(4):367-73. DOI: 10.1097/JCP.0000000000000346. View

17.

Siu C, Harvey P, Agid O, Waye M, Brambilla C, Choi W . Insight and subjective measures of quality of life in chronic schizophrenia. Schizophr Res Cogn. 2016; 2(3):127-132. PMC: 4788499. DOI: 10.1016/j.scog.2015.05.002. View

18.

. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511(7510):421-7. PMC: 4112379. DOI: 10.1038/nature13595. View

19.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-62. DOI: 10.1016/S0140-6736(13)60733-3. View

20.

Stone J . Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?. Ther Adv Psychopharmacol. 2013; 1(1):5-18. PMC: 3736896. DOI: 10.1177/2045125311400779. View